Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Abstract

Rationale: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. Patient concerns: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. Diagnosis: They were diagnosed as refractory nasopharyngeal carcinoma. Interventions: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. Outcomes: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. Lessons: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

“…One case study reporting three patients with refractory NPC receiving continuous infusion of endostar (15 mg/m 2 /day, 30-day cycle) combined with chemoradiotherapy consisting of intravenous drip of nedaplatin (80 mg/m 2 /day on days 1 and day 28) plus continuous low-dose intravenous infusion of 5-FU (200 mg/m 2 /day, 30-day cycle) plus concurrent low dose radiation (100 to 120 cGy, at first cycle) saw that the two-cycle regimen could decrease the load of EBV DNA in plasma and regress tumor; two of which had complete response and the other had partial response [ 425 ]. Efficacy should be replicated in trials enrolling larger sample size with longer follow-up duration.…”